Antibody structure, instability, and formulation

被引:698
作者
Wang, Wei [1 ]
Singh, Satish [1 ]
Zeng, David L. [1 ]
King, Kevin [1 ]
Nema, Sandeep [1 ]
机构
[1] Pfizer Inc, Global Biol, Chesterfield, MO 63017 USA
关键词
biotechnology; stabilization; protein formulation; protein aggregation; freeze drying/lyophilization;
D O I
10.1002/jps.20727
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The number of therapeutic monoclonal antibody in development has increased tremendously over the last several years and this trend continues. At present there are more than 23 approved antibodies on the US market and an estimated 200 or more are in development. Although antibodies share certain structural similarities, development of commercially viable antibody pharmaceuticals has not been straightforward because of their unique and somewhat unpredictable solution behavior. This article reviews the structure and function of antibodies and the mechanisms of physical and chemical instabilities. Various aspects of formulation development have been examined to identify the critical attributes for the stabilization of antibodies. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:1 / 26
页数:26
相关论文
共 118 条
  • [1] Akers Michael J, 2002, Pharm Biotechnol, V14, P47
  • [2] MONITORING OF IGG ANTIBODY THERMAL-STABILITY BY MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY AND MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS-SPECTROMETRY
    ALEXANDER, AJ
    HUGHES, DE
    [J]. ANALYTICAL CHEMISTRY, 1995, 67 (20) : 3626 - 3632
  • [3] Amphlett G, 1996, Pharm Biotechnol, V9, P1
  • [4] ANDYA J, 2004, PROTEIN FORMULATION
  • [5] Andya JD, 2003, AAPS PHARMSCI, V5
  • [6] The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody
    Andya, JD
    Maa, YF
    Costantino, HR
    Nguyen, PA
    Dasovich, N
    Sweeney, TD
    Hsu, CC
    Shire, SJ
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (03) : 350 - 358
  • [7] [Anonymous], [No title captured]
  • [8] PRACTICAL CONSIDERATIONS IN THE PRODUCTION, PURIFICATION, AND FORMULATION OF MONOCLONAL-ANTIBODIES FOR IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY
    BOGARD, WC
    DEAN, RT
    DEO, Y
    FUCHS, R
    MATTIS, JA
    MCLEAN, AA
    BERGER, HJ
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1989, 19 (03) : 202 - 220
  • [9] Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice
    Braun, A
    Kwee, L
    Labow, MA
    Alsenz, J
    [J]. PHARMACEUTICAL RESEARCH, 1997, 14 (10) : 1472 - 1478
  • [10] Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation
    Breen, ED
    Curley, JG
    Overcashier, DE
    Hsu, CC
    Shire, SJ
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (09) : 1345 - 1353